DUBLIN–(BUSINESS WIRE)–The “Global TCR Therapy Market, 2022-2035: Distribution by Target Indication, Target Antigen, Key Players and Key Geographies: Industry Trends and Global Forecasts, 2022-2035” report has been added to ResearchAndMarkets.com’s offering.
This report features an extensive study of the current market landscape and future potential of TCR-based therapies. The report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of the biopharmaceutical industry.
Modified T-cell receptor therapy (TCR therapy) is an emerging class of adoptive therapy that employs genetically modified lymphocytes to target specific tumor markers. Their tumor-cell killing efficacy may be primarily attributed to the fact that they are pre-sensitized to cancer specific antigens; this enables such interventions to selectively target and eliminate tumor cells from the body of a host with negligible treatment-related side effects.
Ongoing and planned clinical research initiatives in this direction are driven by encouraging results achieved in past trials, which were mostly focused on various hematological cancers and solid tumors. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the TCR therapy market is likely to witness significant growth in the foreseen future.
Need for TCR Therapies for the Treatment of Various Types of Cancer
Modified T-cell receptor therapy (TCR therapy), an upcoming class of cell-based interventions, is a promising therapeutic modality. Similar to other T-cell based interventions (such as CAR-T cells and TILs), TCR therapies are designed to target the underlying causes (or primary mediators) of a clinical condition.
Additionally, this emerging class of biologics is believed to possess the potential to cater to unmet pharmacological needs across both oncological and non-oncological disorders, even those where small molecule drugs have proven to be inadequate. Although TCR-based immunotherapies are still considered an experimental approach, several clinical studies demonstrate the efficacy and therapeutic superiority of TCR cell products.
Current Market Landscape of TCR Therapies
Presently, more than 100 industry and non-industry players across the globe are evaluating the potential of over 190 TCR-based immunotherapies for the treatment of various oncological and non-oncological disorders.
It is worth highlighting that, in January 2022, the FDA approved the first TCR-based therapy, Kimmtrak (Immunocore), for the treatment of adult patients with unresectable or metastatic uveal melanoma. More than 90% of the therapy candidates that are being developed to target a wide range of disease indications are autologous in nature. Further, NY-ESO-1 and MAGE emerged as the most popular target antigens in this domain.
Rising Interest in TCR Therapies
The growing interest in this field is reflected in the notable increase in partnerships inked (close to 140 deals inked in the past decade; CAGR 23%) by several industry players and academic / research institutes. Additionally, various investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 11 billion across 140 instances, since 2007.
Further, in the last 10 years, close to 110 clinical trials have been registered across different geographies for the evaluation of TCR therapies. Mostly driven by the need for effective treatment options for cancer, the TCR therapy pipeline is expected to steadily grow over the coming years. Moreover, clinical success is likely to draw in investments that are likely to support the ongoing and anticipated therapy development initiatives.
Market Size of the TCR Therapy Market
With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of 51% in the next decade. Specifically, in terms of target indication, the market is anticipated to be driven by nasopharyngeal carcinoma, multiple myeloma, and head and neck carcinoma.
Additionally, more than 80% of the market is anticipated to be captured by players based in Europe and Asia-Pacific in 2035. Overall, we are led to believe that the global TCR therapy market is poised to witness significant growth in the foreseen future.
Who are the Key Players in the TCR Therapy Market
Examples of key players engaged in this domain (which have also been captured in this report) include Adaptimmune Therapeutics, Alaunos Therapeutics, blubird bio, Bristol Myers Squibb, Cellular Biomedicine Group, China Immunotech, Gilead Sciences, GlaxoSmithKline, Immatics, Immunocore, Intellia Therapeutics, Lion TCR, Takara Bio, TCRCure Biopharma, and Zelluna Immunotherapy.
For more information about this report visit https://www.researchandmarkets.com/r/tvi9rw
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900